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1. State of art 
Cardiac Fibrosis 
Cardiovascular diseases (CDV) are one of the most severe disorders and cause of death worldwide, 
are a rapidly arising problem in industrialized and developed countries (Henderson et al., 2020). 
World Health Organization mentioned that around 17.9 million people die of CDV each year mainly 
from heart attack and stroke, accounting for 30% of all global deaths. By 2030, nearly 23.6 million 
people might die from CDV, remaining the leading cause of death (WHO, 2017). Almost in all 
cardiovascular diseases such as hypertension, myocardial infarction, and aortic valve stenosis (Fang 
et al., 2017) appears a common hallmark, cardiac fibrosis (Biernacka & Frangogiannis, 2011). Fibrosis 
is not a disease (Henderson et al., 2020), initially acts as a beneficial process of repaired but the 
maladaptive response to injury develops the accumulation of extracellular matrix components, mainly 
collagen (Murtha et al., 2017) producing chamber dilation and hypertrophy as pathological changes 
at the  injured tissue (Lu et al., 2017; Murtha et al., 2017); as a result, the size of the fibrotic tissue is 
expanded, thus causing cardiac function disease and cardiac death (Ding et al., 2020; Z. Fan & Guan, 
2016).  
Different cell types are found in the heart (Nandi & Mishra, 2015) three main types related to the 
number of cells are cardiomyocytes known commonly as heart cells, endothelial cells, and fibroblasts 
(Talman & Ruskoaho, 2016). Pinto et al., 2016 study revealed that cardiomyocytes and endothelial 
cells are the most abundant cell type in relation to fibroblasts that represent the third part of cardiac 
cellular composition (Figure 1). In the myocardium are present three types of collagen fibers, type I, 
III and IV being the main fibers type I (80%) and III (10%) (Gallego Muñoz et al., 2019). 
 It is known that fibrotic response is mainly activated by cardiac fibroblasts (Aujla & Kassiri, 2021). 
Cardiac fibroblasts (cFBs) are flat, spindle-shaped (Gibb et al., 2020; Tian et al., 2017)  mesenchymal 
cells origin and main producers of extracellular matrix to maintain a normal cardiac environment; 
therefore act as regulator cells to keep homeostasis of the extracellular matrix (ECM) which acts as a 
scaffold for cardiac cells (DeLeon-Pennell et al., 2020) in addition, are involved in structural, 
mechanical, and electrical cardiac function.  
 
Figure 1. Most abundant cardiac cell types and its percentage of abundance in heart (Pinto et al., 2016). 
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Activation of cFBs starts with a pathological stimulus which trigger a profibrotic signaling having as 
result an excess of ECM proteins, this stimulation can be done by different signaling such as 
cytokines, renin angiotensin system and others (Ranjan et al., 2019). It is known that the major 
signaling effector of cFBs transdifferentiation into myofibroblasts (myoFBs) is the cytokine TGF β. 
Myofibroblasts transdifferentiation consists of two stages: the first stage consists of the adhesion of 
the complexes followed by the formation of stress-fiber network that helps the migration of proto-
myofibroblast to the affected tissue; while in the second stage proto- myofibroblasts become mature 
myofibroblast which secrete alpha-smooth muscle actin (α-SMA) protein (Yousefi et al., 2020) known 
as the main marker of myofibroblasts (Parichatikanond et al., 2020). Mature myofibroblast produce 
an excessive amount of extracellular matrix proteins such as collagen I, III, IV, fibronectin and a 
different type of cytokines (Yousefi, et al., 2020);  in addition the development of scar tissue (Figure 
2) (Leask, 2015). Moreover, activated fibroblasts also overexpress ECM components been involved 
in the profibrotic process under TGF β stimulus (Melzer et al., 2020).  
The action of fibroblasts can produce different types of fibrosis. It should be mentioned that the 
classification of cardiac fibrosis depends on the place and cause (Fan et al., 2012) but, reactive 
interstitial and reparative fibrosis are the most common (Murtha et al., 2017). Interstitial fibrosis is 
the process of cardiomyocyte replacement (Ranjan et al., 2019)  due to the activation of fibroblasts 
responsible for degrading the stroma and depositing excess ECM proteins, hindering the contractile 
capacity of the myocardium (Aujla & Kassiri, 2021); on the other hand, replacement fibrosis is a 
process of repair (Murtha et al., 2017) in which lost cardiomyocytes are re-emerged with collagen 
scars (Ranjan et al., 2019) to maintain the myocardial structure (Aujla & Kassiri, 2021). 
 




TGF β role in cardiac fibrosis 
Studies have demonstrated that the cytokine transforming growth factor β (TGF-β) is the major 
contributor in the activation of fibrotic responses (Leask, 2007) specially triggers the overexpression 
of ECM compounds during cardiac fibrosis (Ma et al., 2018). Three isoforms of TGF β have been 
identified (TGF β1, TGF β2 and TGF β3) encoded by three different genes (Ma et al., 2018) and 
secreted by many types of cells, for example macrophages and damaged cardiomyocytes (Liu et al., 
2017). Studies have described TGF β1 as the most prevalent isoform implicated in fibrosis and found 
in mammalian tissues (Biernacka et al., 2011).  TGF β is involved in the activation of fibroblasts and 
in the transformation of fibroblasts into myofibroblast once it binds to its type I and II receptors and 
to TGF β/Smad signaling (Liu et al., 2017).  
The cytokine TGF β is present in a healthy heart  as a latent complex retained in the ECM (Kong et 
al., 2014; Parichatikanond et al., 2020), it is composed by three proteins such as TGF β, latency 
associated peptide (LAP) and latent TGF β binding proteins (LTBPs) which prevents it from binding 
to its receptors (Yousefi et al., 2020). Excess TGF β  causes the change from a latent complex to an 
active form by binding to its receptor being released from ECM (Kong et al., 2014); a signaling 
cascade is initiated by the binding of TGF β to its heterodimeric transmembrane receptors type I 
(TGFβR1) and type II (TGFβR2) interceded mainly by Smad cell mediators in the canonical route of 
signaling (Parichatikanond et al., 2020).  
TGF β type I receptor is a serine-threonine kinase, also named activin linked kinase 5 (ALK5) (Leask, 
2015). In the canonical pathway in the presence of TGF β ligand, this receptor assists in the 
phosphorylation of Smad2 and 3. Phosphorylated Smad2/3 proteins binds to Smad 4 (mediator 
Smad) forming a heteromeric complex followed by a nuclear translocation to activate gene expression 
of pro-fibrotic genes such as collagens and fibronectin (Gibb et al., 2020; Parichatikanond et al., 2020; 
Yousefi et al., 2020) (Figure 3).    
 
Figure 3. Scheme of canonical pathway of activation of TGF β (Parichatikanond et al., 2020). Created with BioRender.com. 
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TGF β activates other non-canonical pathways which include mitogen-activated protein kinases 
(MAPK) pathways such as c-Jun- N-terminal (JNK), extracellular signal-regulated kinase (ERK) and 
p38 MAPK, phosphatidylinositol 3 kinase (PI3K) and Rho-like GTPases (Biernacka et al., 2011; 
Finnson et al., 2020; Travers et al., 2016). 
TGF β signaling cascade presents several mediators and partners helping the efficiency of profibrotic 
protein expression. Those mediators are potential targets to reduce fibrosis due to blocking TGF β 
causes important side effects in patients. One such mediators is known to be heat shock 90 chaperone 
(Hsp90), the absence of which reduces collagen expression in vitro and in vivo by participating at plasma 
membrane level as well as intracellularly (Cáceres et al., 2018) in cardiac fibrosis models. 
 
Hsp90 
Heat shock protein 90 (Hsp90) is a molecular chaperone and one of the main and the most studied 
heat shock proteins (HSPs) with a molecular weight of 90 kDa (Colunga Biancatelli et al., 2020; Hoter 
et al., 2018). There are four types, Hsp90 α (I &II) and Hsp90 β are in the cytoplasm whereas GRP94 
in endoplasmic reticulum (ER) and TRAPI in the mitochondria (Hoter et al., 2018; X. Zhang et al., 
2021); being the main ones Hsp90 α and β (Zhang et al., 2021). Hsp90 is involved in processes of 
stabilization of TGF β receptors (Cáceres et al., 2018; Hoter et al., 2018; Tomcik et al., 2014; Wrighton 
et al., 2008).  It is known that fibroblasts and some other cell types secrete Hsp90 in small amounts 
(Hoter et al., 2018), this extracellular Hsp90 forms a complex with the TGF β1 receptor thus enabling 
TGF β to bind to its receptor triggering ECM compounds gene expression (García et al., 2016; X. 
Zhang et al., 2021). Therefore, different studies showed that in fibrotic diseases Hsp90 inhibitors 
such as 17-AAG, 17-DMAG, geldanamycin, radicicol and other new therapeutic strategies can reduce 
fibrogenesis by inhibiting Hsp90 and blocking TGF β1 signaling cascade, thus ECM synthesis 
(Cáceres et al., 2018). 
Tomcik et al., 2014 study demonstrated that Hsp90 inhibition suppresses profibrotic effects and 
revealed that 17 DMAG inhibitor avoid the accumulation of the phosphorylated Smad2/3 complex 
in the nucleus, preventing fibroblast transdifferentiation into myofibroblast. Also, in García et al., 
2016 study was demonstrated that inhibition of extracellular Hsp90 leads to a reduction in collagen I 
expression in TGF β-activated mouse embryonal fibroblasts. As well as Cáceres et al., 2018 study 
that showed a decreased of collagen expression in myocardial fibrosis using an engineered 
fluorescent-labeled Hsp90 protein inhibitor named CTPR-488 which breaks into TGF β/Hsp90 
complex. Furthermore, in Solopov et al., 2019 study was validated that Hsp90 inhibitor AUY-922 
prevents the development of chronic lung injury and pulmonary fibrosis by exposure to nitrogen 
mustard. In the same way in Marinova et al., 2020 study was used Hsp90 inhibitor AUY-922 in 
treatment of chronic lung injury and pulmonary fibrosis but given by exposure to HCl, same way 
they confirmed the efficiency of this inhibitor blocking adverse effects. Colunga Biancatelli et al., 
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2020 used Hsp90 inhibitors to modulate proteome involved in idiopathic pulmonary fibrosis (ipf) by 
interfering with TGF β (Smad and non Smad) intracellular signaling.  
 All these results point to Hsp90 as a good target to reduce fibrosis. The design of new therapies that 
maintain the chaperone activity of Hsp90, and thus cellular homeostasis, while reducing the ability of 
Hsp90 to interact with TGF β signaling mediators, seems to be a good therapy in fibrotic diseases. 
 
Anti-fibrotic therapy: cTPRAu-390 
The engineered tetratricopeptide repeat scaffold (TPR) are protein domains mediating protein-
protein interactions and present in different proteins (Cortajarena et al., 2010; Perez-Riba & Itzhaki, 
2019). It consists of 34 amino acids of 2 to 20 repeats giving a coiled and superhelical shape (Perez-
Riba & Itzhaki, 2019). Taking this domain as scaffold, our collaborators at CIC-BiomaGune 
generated nanoclusters based on non-functional TPR modules bind to a functional TPR that 
specifically binds Hsp90. 
We named this nanocluster construction cTPRAu-390 nanocluster, and it can inhibit cardiac fibrosis 
by blocking TGF β signaling pathway in vitro and in vivo (Cáceres et al., 2018). Because the functional 
TPR binds to C-terminal Hsp90 region causing a change in its conformation and releasing TGFβRI 
thus inhibiting fibrosis but without affecting its ATPase function (Figure 4), also gold molecules 
were conjugated to confer the nanocluster fluorescence becoming a theragnostic tool that is able to 
localize the injury and treat it (Aires et al., 2021; Cáceres et al., 2018). To improve the in vivo 
biodistribution of the nanocluster and to avoid the first hepatic step if it happens, we want to use a 
biocompatible vehicle as drug delivery. 
 
Figure 4. Scheme of the molecular model of interaction of Hsp90 (cyan and dark blue)  with the nanocluster cTPRAu-390 
(violet) and its conformational change that triggers the release of TGFβRI (orange) (Cáceres et al., 2018).   
 
Extracellular vesicles as biotherapeutic molecules and nanocarriers for drug 
delivery  
Cell-to-cell communication is essential in all multicellular organisms. This process is given by 
emission of different type of signals, nowadays it is known that this communication can also be 
carried out by biological complexes called extracellular vesicles (Tkach & Théry, 2016). International 
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Society for Extracellular Vesicles (ISEV) defines extracellular vesicles (EVs) as nanoparticles released 
by cell and composed of a lipid bilayer membrane without functional nucleus and not able to replicate 
(Théry et al., 2018), carrying active biomolecules such as RNAs, proteins and lipids (Tkach & Théry, 
2016), initially were though that they were secreted for the removal of unnecessary compounds from 
the cell, but nowadays it is known that EVs are more than just a waste (Van Niel et al., 2018); they 
are able to transport cargo to the recipient cell (Zaborowski et al., 2015) making them important 
regulators in cell to cell communication diagnostic tools  and as drug delivery vehicles (Boulanger et 
al., 2017; El Andaloussi et al., 2013). Extracellular vesicles are secreted by all cell types and can be 
found in bodily fluids such as urine, blood, and saliva (Doyle & Wang, 2019; Ha et al., 2016; Théry 
et al., 2018).  
ISEV has suggested that EVs can be classified according to the following features: physical 
characteristics such as size, chemical composition, and the quantity of charge on their surface 
(Gandham et al., 2020). Based on their intracellular origin exist three types of extracellular vesicles: 
microvesicles, exosomes and apoptotic bodies (Ha et al., 2016).  
Microvesicles are originated by directly budding and fission of the plasma membrane (Zaborowski et 
al., 2015). ADP-ribosylation factor 6 (ARF6) is responsible for initiating the signaling cascade via 
phospholipase D (PLD) activation which engages extracellular signal- regulated kinase (ERK) binding 
to the plasma membrane, and this kinase activates the phosphorylation of myosin light-chain kinase 
(MLCK) triggering the release of microvesicles (Figure 5) (Akers et al., 2013) with a ranging size 100 
nm to 1 µm (Van Niel et al., 2018). Due to the method by which microvesicles are obtained, they 
contain transmembrane proteins as tetraspanins (CD9, CD63, CD81 & CD82), another found are 
cytoskeleton proteins (Actin, tubulin), heat shock proteins, integrins involved in the attachment to 
target cells and proteins with post transcriptional modifications (Doyle & Wang, 2019).  
 
Figure 5. Biogenesis of microvesicles by budding and fission of plasma membrane (Akers, 2013). ARF: ADP-ribosylation 




In the other hand, exosomes are smaller than microvesicles with a ranging size from 40 to 130 nm, 
are formed from the endosomal pathway. Multivesicular bodies (MVBs) developed from early 
endosomes. By inward budding of the multivesicular bodies intraluminal vesicles (ILVs) are formed 
inside MVBs. MVBs fusion with the plasma membrane, release ILVs outside the cell becoming 
exosomes (Figure 6)(Akers et al., 2013; de Abreu et al., 2020; Yáñez-Mó et al., 2015). It is known 
that endosomal sorting complex required for transport (ESCRT) is involved in the formation of ILVs 
which is an intricate protein composed of four proteins (0, I, II & III); furthermore, ESCRT 
mechanism is triggered by the identification and attachment of ubiquitinated proteins to endosomal 
specific membrane domains through the ESCR-0 ubiquitin-binding subunits that interact with 
ESCRT-I and ESCRT-II complexes, and this complex combines with ESCRT-III complex (involved 
in the budding process). Finally, after buds are cleaved to form ILVs, sorting protein Vsp4 provides 
energy necessary for ESCRT-III complex detachment from MVB membrane (Zhang et al., 2019). 
ESCRT-III is thus recruited to the ESCRT-I and II site by the Alix protein, which binds 
simultaneously to TSG101 component of the ESCRT-I complex and to charged multivesicular body 
protein 4 (CHMP4), ESCRT-III component (Akers, et al., 2013). Following proteins are part of 
exosomes composition: tetraspanins such as CD9, CD63 & CD81; major histocompatibility complex 
II (MCHII); membrane transport & fusion proteins (Annexins, Flotillin-1, Syntenin-1 & GTPases); 
cluster of differentiation (CD); heat shock proteins (Hsps); Ras related protein (Rab); adhesion 
molecules known as integrins and other such as TSG101, Hsp90 β, Syntenin-1 & Allix embedded 
into exosomes after its formation (Figure 7) (Doyle & Wang, 2019; Zaborowski et al., 2015). 
However, there is still a lack of specific markers to differentiate microvesicles from exosomes (Doyle 
& Wang, 2019).  
 
Figure 6. Scheme of exosomes biogenesis and its different types of compounds. Exosomes carry cellular components 
DNA, miRNA, mRNA, and intracellular proteins such as tetraspanins, Allix and TSG101 (modified of Ha et al., 2016; 




Figure 7. Scheme of various exosomes components such as MHCII: major histocompatibility complex II, CD: cluster of 
differentiation, Rab: Ras-related, Hsp: heat shock proteins, tetraspanins, etc.; it also contains different type of lipids as 
cholesterol, sphingomyelin. Exosomes contain nucleic acid including miRNA.  (Ha et al., 2016). 
Finally, during apoptosis the cells are reduced and fragmented into apoptotic bodies (Figure 8), 
having a ranging size from 0.5 to 2 µm (Janas et al., 2015) are release by dependent on Rho associated 
kinase I (ROCK) with ATPase activity (Sluijter et al., 2014). The presence of organelles inside the 
vesicles is what defines them (Van Dommelen et al., 2012) it also contains glycosylated proteins and 
chromatin (Doyle & Wang, 2019). 
 
Figure 8. Development of apoptotic bodies during apoptosis. Created with Biorender.com 
 
Exosomes and microvesicles are similar in their appearance, overlap in sizes and are often common 
in composition, which makes it difficult to identify their origin upon isolation from biological fluids 
or extracellular medium (Van Niel et al., 2018).  
It seems that EVs can carry different cargoes such as lipids, proteins, and nucleic acids. Extracellular 
vesicles will exhibit a set of cell type-specific proteins that account to their specific targets and roles 




Figure 9. Different biomolecules carried by exosomes and microvesicles (Van Niel et al., 2018). 
de Abreu et al., 2020 study mentioned that an important feature of extracellular vesicles is their 
negative surface charge, therefore nanoparticles near neutral charge are most stable in the circulation 
in comparison to highly charged nanoparticles.  
Extracellular vesicles are ideal as drug delivery vehicle due to their long circulating half-life, 
biocompatibility being well behave by human organism, inherent capacity to target tissues, in addition 
is capable to be internalized into the cell, also can act as a therapeutic tool and present minimal or no 
implied toxicity (Doyle & Wang, 2019; Ha et al., 2016). 
The vesicles of interest in this study are microvesicles and exosomes due to their capacity of cell 
carriers without immune response and their high potential of carrying the desired drug-cargo. 
 
2. Objectives 
This study has six objectives:  
1. Purification of the extracellular vesicles from NIH-3T3 fibroblasts. 
2. Characterization of EVs by electron microscopy, dynamic light scattering, flow cytometry 
and western blotting technique. 
3. Analysis of the expression of the main profibrotic genes (Col I, Col III and Fibronectin) 
after microvesicles administration to NIH-3T3 cells. 
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4. Evaluation of EVs encapsulation with a therapeutic strategy and analysis of the expression 
of the main profibrotic genes (Col I, Col III and Fibronectin) after their administration in 
NIH-3T3 cells. 
5. Verification of the internalization of encapsulated and non-encapsulated EVs in NIH-3T3 
cells.   
6. Observation of in vivo distribution in a fibrotic model mouse of fluorescent EVs. 
 
3. Materials and methods 
Isolation of extracellular vesicles 
Cell culture 
Mouse embryonal fibroblasts NIH-3T3 cell line was used in this study. Cells were cultured in Dulbeco 
Modified Eagle’s Medium High Glucose (DMEM) supplemented with 10% Fetal Bovine Serum 
(FBS) and 1% penicillin- streptomycin. Cultured conditions were 37°C 100% of humidity and 5% of 
CO2 using Thermo Scientific Forma 381 Steri Cycle CO2 Incubator. We also used a stable fluorescent 
cell line 3T3 mKATE created in our group that express the fluorescence protein mKATE 2 binds to 
all cell membranes, which also confers fluorescence to the EVs released by these cells. 
EVs isolation protocol 
Fourteen 150 mm plates with NIH-3T3 cells at 75% confluence were used, cells were washed with 
PBS and cultured for 5 days without EVs supplementing the medium with EVs depleted FBS. Then, 
the medium containing EVs released from NIH-3T3 cells was collected to start the isolation. 
Since the size between microvesicles and exosomes differs from each other, there are different 
methods for the isolation of extracellular vesicles, the most used technique being the differential 
centrifugation (Zaborowski, Balaj, Breakefield, & Lai, 2015). First, to eliminate cellular debris and 
death cells was done a first centrifugation, carried out at 2000 × g for a time of 30 minutes, then 
supernatant was transferred to polyallomer tubes correctly calibrated to be used in an AH29/36 rotor 
(Thermo Scientific Sorvall). A first ultracentrifugation was performed at 10,000 × g for 90 minutes 
to pellet the microvesicles. The supernatant was ultracentrifuged at 100,000 × g for 90 minutes to 
pellet exosomes. Part of the supernatant was saved as control. Microvesicle and exosome pellets were 
washed twice in PBS EVs free by ultracentrifugation (OptimanTM MAX-UP Ultracentrifuge) at their 
respective speeds for 40 minutes and resuspended in the final volume (70 µL of PBS EVs free).     
To check the success of the isolation we measured the protein amount using spectrophotometer 





ISEV recommends characterizing EVs by at least three techniques. For this study, NIH-3T3-derived 
EVs were characterized by four techniques: Electron microscopy, Dynamic light scattering, Flow 
cytometry and Western blotting. 
Electron microscopy Negative Staining  
EVs characterization is commonly achieved by negative staining, a technique normally performed in 
bacteria or virus, and imaged in a transmission electron microscope (JEOL- JEM 1011 equipped with 
a high resolution Gatan digital camera). Protocol consists of applying 3 µL of EVs (previously 
obtained by ultracentrifugations) on the TEM-grid 10 seconds and blotted for 3 seconds; after that, 
sample was immediately stained with 10 µL of 0.5% uranyl acetate for 10 seconds and blotted again. 
Grid was air-dried 5 minutes and placed into a grid box until its observation (minimum drying time 
before observation: overnight). 
Dynamic Light Scattering  
To define the electric charge of the EVs under study we utilized dynamic light scattering using 
Malvern Zetasizer Ultra MADLS ®. We used PBS EVs free as control buffer, a 1:100 dilution was 
prepared, and samples were placed into 12 mm o.d. square glass cell cuvettes (PCS1115). Three 
measurements of each population of extracellular vesicles were performed and averaged. 
Flow cytometry  
Flow cytometry was carried out to measure the concentration of isolated EVs population. 
Following characterization protocol MASCQuant® Analyzer cytometer, was used to measure the 
number of EVs per sample. Before measurement, channels were set up to hyper log (hlog), triggered 
on SSC to 4 and secondary trigger was shut off. An unstained control PBS EVs free was measured 
to evaluate background noise. Autofluorescence was evaluated by the measurement of unstained EVs 
samples (EVs from NIH-3T3 cells). To measure the samples, we performed 1:10 dilution in PBS 
EVs free (Rotator et al., 2015). 
Western blotting  
ISEV recommends that EVs must be characterize by at least three positive protein markers including 
at least one: transmembrane/lipid-bound protein or cytosolic protein. In this technique were used 
three different biological samples for each EVs type. To detect EVs marker proteins in our EVs 
samples the technique used was western blotting (WB). We measured the protein content of 
exosomes and microvesicles and 140 µg of EVs protein were loaded in each well, NIH-3T3 mKATE 
lysis, NIH-3T3 lysis, buffer lysis, depleted medium and the supernatant saved as mentioned in 
isolation section above, were used as control. Samples were separated by size in a 12% polyacrylamide 
gel (Flotillin-1 and Syntenin-1 antibodies) and in 15% (CD81 antibody) for 10 minutes at 100 V and 
then 90 minutes at 180 V with SDS-PAGE. Polyvinylidene difluoride (PVDF) membranes were used 
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for protein transfer. Membranes were activated 10 minutes in methanol. Transfer conditions were 90 
minutes at 300 mA. After the transfer process membranes were blocked with 5% BSA (Bovine Serum 
Albumin)– TBS for 1 hour at room temperature in agitation. Then, membranes were incubated with 
primary antibodies (Flotillin- 1, Syntenin- 1 or CD81) overnight at 4°C in agitation. Three washes 
with TBST 10 minutes each were done, and then secondary fluorescence antibody against the specie 
of the primary antibody were incubated for 1h under dark conditions at room temperature in 
agitation. Finally, three TBST washes were done, and the membranes were visualized by Odyssey 
CLx Near-Infrared Fluorescence Imaging System. Images were analyzed using Image J software.  
To confirm success transfer, gels were stained with Coomassie Blue Stain and membranes with 
Ponceau S Staining solution on agitation for 10 minutes and images were taken after TBST washes 
(Figure 10). 
 
Figure 10. Unspecific protein detection to confirm a successful electrophoresis and transfer a) gel stained with blue 
coomasie; and a successful protein transfer to the membrane: b) membrane stained with red poceau. Source: author 
 
cTPRAu-390 encapsulation into EVs  
Isolated microvesicles (140 μg) and exosomes (80 μg) were mixed in a final concentration 25 µM of 
cTPRAu-390 and were incubated at room temperature in agitation for 15 minutes. Then, to increase 
the permeability of the plasma membrane of the extracellular vesicles and allow the nanocluster to 
enter into them, an electroporation technique was used. Samples were placed into electroporation 
cuvettes and electroporated using BIO-RAD Gene Pulser II Electroporator and Capacitance 
Extender Plus. Electroporation conditions were 400 V 125 µF two pulses (Figure 11). For 
subsequent microscopy visualization, the samples were stained with 3 µL of BODIPY™ TMR-X 
NHS Ester (Succinimidyl Ester) (Thermo Fisher Scientific) (fluorescent dye) that binds lipids 
unspecifically; and incubated in agitation for 15 minutes. In addition, to eliminate excess of dye and 
non- encapsulated cTPRAu-390, PBS EVs free washes were done by ultracentrifugation (at 10,000 
× g microvesicles & 100,000 × g exosomes) for 40 minutes at 4°C. Finally, the pellet was resuspended 
in PBS EVs free. To in vivo study, BODIPY was not used to stained encapsulated cTPRAu-390 into 
EVs because its wavelength is not appropriate to be used in the Spectrum In vivo Imaging System 





Figure 11. Scheme of the encapsulation of cTPRAu-390 into EVs by electroporation. Created with BioRender.com 
 
Flow cytometry analysis to detect the encapsulation of the therapy into EVs 
MASCQuant® Analyzer cytometer was used to analyze samples as described in Cytometry section 
with addition and set up of cTPRAu-390 and BODIPY fluorescence channels. Set aside control 
samples as described in encapsulation section were analyzed.  
 
Different treatments for analyzing profibrotic gene expression in NIH-3T3 
cells. 
80,000 NIH-3T3 cells were seeded into T12 dishes with 3 mL medium. After 24 h with a 75% of cell 
confluence, cells were washed with PBS for treatments to be applied. 1 ng/mL TGF β and medium 
up to 1 mL were placed in each well. The first column was used as a control and no treatment was 
applied. 150 μg (protein amount) of microvesicles non encapsulated were applied into the second 
column and in the third one was added cTPRAu-390 encapsulated into (150 μg protein amount) 
microvesicles (Figure 12). In addition, the dish with treatments was incubated for 24 h or 36 h, after 
this time the medium was discarded, and the plate was stored at -80°C. The same process was 
performed for exosomes with the difference in the concentration of protein used, which was 80 μg 




Figure 12. Scheme of different treatments. NIH-3T3 cells cultured on T12 dishes with the different treatments applied to 
each one of the wells: in every well was added 1ng/mL of TGF β; second column, 150 µg microvesicles or 80 µg exosomes 
& third column, cTPRAu-390 encapsulated into EVs. Created with BioRender.com 
 
Study of gene expression of the genes of interest 
RNA isolation 
Once the cells described in the above section were frozen, we defrost cells and proceeded to RNA 
isolation, following NZYol (nzytech, MB18501, 100 mL) protocol as follows. 
In the first step, cells were lysed by applying NZYol (1 mL/5×106 cells) and incubated for 5 minutes 
at room temperature. 
The phases were separated by adding chloroform, shaken briefly, and incubated at room temperature 
for 3 minutes. Samples were centrifuged (Centrifuge 5810R, Eppendorf) at 12,000 × g for 15 minutes 
at 4°C, then aqueous phase that contains RNA (Figure 13) was carefully transferred into new tubes. 
RNA was precipitated with cold isopropanol, incubated for 10 minutes at room temperature, and 
centrifuged for 10 minutes at 12,000 × g at 4°C. Then washed with cold 75% ethanol (1 mL of 
ethanol/1 mL NZYol), centrifuged at conditions mentioned above, the supernatant was discarded 
and well air dried before resuspended in RNase- free water. Samples were quantified by absorbance 
reading in the spectrophotometer (NanoDropTM 2000c, Thermo Fisher Scientific). 
  
Figure 13. Separation of the different phases in RNA isolation, at the bottom DNA, at the middle protein and at the top 




After obtaining the purified RNA, the cDNA was obtained using High-Capacity cDNA Reverse 
Transcription (RT) Kit, 1000 reactions (Thermo Fisher Scientific PN 4368813). We prepared 2× RT 
master mix (Table 1). 0.1 µg of ARN was used, water up to 10 µL and mixed with 10 µL of master 
mix. Thermal cycler conditions are illustrated in Table 2. 
Table 1. 2× RT Master mix components to perform reverse transcription reaction to obtain cDNA from RNA. (Thermo 
Fisher Scientific PN 4368813) 
Component Volume/ Reaction (µL) 
10× RT Buffer 2.0 
25× RT dNTP Mix (100mM) 0.8 
10× RT Random Primers 2.0 
MultiScribe TM Reverse Transcriptase 1.0 
Nuclease-free H2O 4.2 
Total per Reaction 10.0 
 
Table 2. Thermal cycler conditions for the reverse transcription reaction to obtain cDNA from RNA (Thermo Fisher 
Scientific PN 4368813) 
Temperature °C Time 
25°C 10 min 
37°C 2 h 
85°C 5 min 
12°C ∞ 
Real time PCR (qPCR) 
To analyze genes expression of Col I, Col III and FN, we performed qPCRs in which the results are 
expressed as relative expression comparing to control sample expression in arbitrary units. We applied 
deltha-deltha Ct method (2-ΔΔct): ΔΔCt= ΔCt (gene of interest) – ΔCt (housekeeping gen). We 
analyzed three conditions: first one corresponds to the control NIH-3T3 cells without treatments, 
the second one corresponds to EVs treatment and the third to cTPRAu-390 (25 μM) encapsulated 
into microvesicles. The same conditions were analyzed with exosomes. 
Once we had cDNA, we proceeded to prepared master mix. PowerUp™ SYBR™ Green Master Mix 
was used in real time PCR for measurement of the expression of genes of interest (Col I, Col III and 
FN). Mouse ribosomal protein S14 was used as housekeeping gen because its basal expression level 
will always be expressed and will be used to relativize with the genes of interest. 1uL of 1:10 dilution 
of the cDNA was used as template. Table 3 illustrates thermal cycler conditions and in Table 4 




Table 3. Thermal cycler conditions to be used in qPCR (Thermo Fisher Scientific Baltics UAB). 
Step Temperature Duration Cycles 
UDG activation 50°C 2 minutes Hold 
Dual-Lock DNA 
polymerase 
95°C 2 minutes Hold 
Denature 95°C 15 seconds  
40 minutes Anneal 60°C 15 seconds 
Extend 72°C 1 minute 
 
Table 4. Primers used for qPCR. 
Gen Sequence 
Col1A1            F TGG GGC AAG ACA GTC ATC GAA TA 
Col1A1            R GGG TGG AGG GAG TTT ACA CG 
Col3A1            F ACC CCA TGA TGT GTT TTG TGG CA 
Col3A1            R CAG GTC CTC GGA AGC CAC TA 
Fibronectine    F CAC CCA CAT GGC AGC TCA CA 
Fibronectine    R ATG GGA ACC CTG AAG CCA GC 
S14                  F AGT GAC TGG TGG GAT GAA GG 
S14                  R CTT GGT CCT GTT TCC TCC TG 
  
 
EVs internalization assay 
Fluorescence microscopy assays to visualize the internalization of EVs into cells 
Nikon fluorescence ECLIPSE Ti2 inverted microscope was used for the visualization of the 
internalization of EVs. The settings of different channels are illustrated in Table 5, mCherry 
corresponds to EVs, GFP to BODIPY fluorescent dye and DAPI to cTPRAu-390 encapsulated into 
EVs. 1 x 105 NIH-3T3 cells were cultured on μ-Dish 35 mm, high microscopy dish which has an 
ibidi polymer coverslip bottom that has a highest optical quality allowing the laser to detect our 
sample, after 24 hours the medium was changed to Leibovitz for microscopy. First the untreated cells 
were recorded, then EVs in the presence of TGF β were added to the cell culture and a 5-minute 
video was performed. Internalization was visualized for both encapsulated and non-encapsulated 
EVs. 
After each video, cells were fixed with formaldehyde for 20 minutes in agitation at room temperature, 














mKATE 588/633 nm mCherry 50 ms 575 nm 10% 578/21 nm 641/75 nm 
BODIPY 544/570 nm GFP 100 ms 470 nm 90% 472/30 nm 520/35 nm 
cTPRAu-390  374/440 nm DAPI 100 ms 395 nm 10% 377/50 nm 447/60 nm 
 
Confocal microscopy assays to detect internalized EVs 
Fixed cells from dishes above mentioned were used to detect EVs internalization. To confirm the 
internalization of the EVs into the cells, the microscope Leica’s confocal Sp5, the oil objective 63 
with a 1.4 mm of opening and 2.5 zoom, were used. Seven z were taken, the step size as 1.13 μm. 
Channels used for the visualization were three: the first corresponds to EVs, the second to the 
fluorescent dye used and the third one to the nanocluster. Technical conditions are illustrated in 
Table 6. 








mKATE 588/633 nm mKATE 594 49% 610 nm 660 nm 
BODIPY 544/570 nm GFP 543 40% of 14% 550 nm 610 nm 
cTPRAU 374/440 nm  DAPI 405 27% 415 nm 415 nm 
 
 
Fibrotic mice generation  
To induce cardiac fibrosis subcutaneous implantation of osmotic minipumps A mid-scapular incision 
was made, and a subcutaneous pocket was created for the micro-osmotic pump (0.25 μl per hour, 14 
days, alzet) to be inserted. The pump was previously filled with an aqueous solution of angiotensin 
II (0.70 mg). The wound was closed with a suture. Mice were monitored daily for any discomfort, 
and they were euthanized 2 weeks after surgery (Figure 14). 
 
In vivo imaging system experiments to visualized EVs distribution in different 
organs in a fibrotic mouse  
The Spectrum In Vivo Imaging System (IVIS) was used to perform these set of experiments in which 
a sequence of images of different wavelengths are separated to remove the autofluorescence of the 
targets and reveal real fluorescence, this process is called Spectral unmixing. Three adult (16–20 weeks 
old) C57BL6 wild type (WT) mice were used for this process. The first mouse was designated for 
cTPRAu-390 encapsulated into microvesicles, the second for encapsulated cTPRAu-390 into 
exosomes and the last one as control. Live animals’ studies were approved by the University of 
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Cantabria Institutional Laboratory Animal Care and Use Committee in compliance with the Guide 
for the Care and Use of Laboratory Animals (ILAR, 1985) and were conducted in accordance with 
the “European Directive for the Protection of Vertebrate Animals Used for Experimental and Other 
Scientific Purposes” (European Communities Council Directive 86/606/EEC).  
After one week, cTPRAu-390 encapsulated into 240,000 exosomes and into 1,600,000 microvesicles 
was injected intraperitoneally (I.P.). In vivo fluorescence image was performed using IVIS to see the 
distribution of the therapy during the time (Figure 14). In vivo photos were taken at times: 0, 24 h 
and 6 days. Mice were euthanized and ex vivo photos were taken.  
Animal handling was performed by accredited researcher and supervisor Jorge Ruiz. 
  
Figure 14. Scheme of the application of osmotic minipumps filled with Angiotensin II (0.70 mg) to induce cardiac fibrosis 
in mice, the administer of the treatment and visualization in IVIS. Created by Biorender.com  
 
4. Results 
Protein concentration of NIH-3T3-derived EVs 
We obtained for microvesicles a protein concentration between 2.548 - 21.623 mg/mL and for 
exosomes between 1.11- 22.600 mg/mL depending on the yield of the isolation. 
 
EVs characterization 
1. Diameter of EVs  
We obtained microvesicles with diameters in a range of 41.55 nm to 158 nm by electron microscopy 
technique, which is in accordance to the describe diameters for this population of vesicles (Figure 
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15) (de Abreu et al., 2020; Lawson et al., 2016; Sluijter et al., 2014). Additional images of microvesicles 
diameters are visualized in Appendix 1.1. 
In the case of the exosome samples, the range was from 31.40 nm to 107.49 nm which also is in 
accordance with previously described exosomes diameters (Figure 16) (de Abreu et al., 2020; Ha et 
al., 2016; Kalra et al., 2016; Lamichhane et al., 2015; Y. Zhang et al., 2019). Additional images of 
exosomes diameters are visualized in Appendix 1.2. 
 
 
Figure 15. Microvesicles diameter size visualized by electron microscopy. a) microvesicles with sizes described, b) better 







Figure 16. Exosomes diameter size visualized by electron microscopy. a) exosomes with sizes described, b) better 
visualization of exosomes shape. 
 
2. Charge measurement of EVs 
We obtained a neutral charge for microvesicles with an average – (0.047±0.01) mV with n1= -0.05155, 
n2=0.05585 and n3=0.03416 (Figure 17). However, a negative charge was obtained for exosomes 






Figure 17. Data obtained from Zsizer DLS of three different measurements of microvesicles. 
 
Figure 18. Data obtained from Zsizer DLS of three different measurements of exosomes. 
 
3. Analysis of the number of EVs per sample  
The first row of the tables in Figure 19 and Figure 20 corresponds to the total counts detected 
and the second row to the counts present in the region defined for EVs. 
 
Image of control PBS (EVs free) buffer used for analysis is attached to Appendix 2.1. In Figure 19, 
on the left side, inside the region mark we obtained a 203,000 microvesicles/mL (counts/mL). This 
sample was 1:10 diluted, thus the stock solution of microvesicles was of 2,030,000 microvesicles/mL 
(counts/mL).  
 
Figure 19. Measurement of microvesicles concentration by forward scatter versus side scatter of 1:10 sample dilution. Red 
mark encloses expected population shape in microvesicles by flow cytometry. 
 
In Figure 20, on the left side, inside the region mark we obtained 11,300,000 exosomes/mL 





Figure 20. Measurement of exosomes concentration by forward scatter versus side scatter of 1:10 sample dilution. Red 
mark encloses expected population shape in exosomes by flow cytometry. 
 
4. Detection of EVs markers 
We checked three biomarkers for EVs such as Flotillin-1 whose expected band size was 47kDa, 
Syntenin-1 whose expected band size was 33 kDa and CD81 whose expected band size was 25kDa.  
As is illustrated in Figure 21, gel stained with Coomassie blue confirms a correct electrophoresis of 
the gel and its transfer to the membrane. We observed Flotillin-1 at the described weight in both 
fraction (Microvesicles and exosomes) in three independent experiments. The relative quantification 
of the band intensities correspondent to Flotillin-1 offered not significant differences between 
Flotillin-1 protein expression of microvesicles and exosomes and showed us that Flotillin-1 is 
expressed in both type of EVs.  
 
Figure 21. a) Quantification (Image J software) of Fotillin-1 protein expression in EVs showing non significance differences 
between microvesicles and exosomes, b) gel stained with Coomassie blue confirm the correct electrophoresis, c, d & e) 
Different membranes with expected Flotilin-1 molecular weight 47kDa. 
 
Next biomarker to analyze was Syntenin-1. We observed Syntenin-1 at the described molecular 
weight in both fractions (Microvesicles and exosomes) in three independent experiments (Figure 
22). Syntenin-1 was 33 kDa and we see that in microvesicles are more quantity of this biomarker. The 
relative quantification of the band intensities offered not significant differences between 
microvesicles and exosomes indicating that Syntnein-1 is expressed in both type of EVs. In Figure 
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22 is also shown gel stained with Coomasie blue, and membrane stained with red ponceau to confirm 
a correct electrophoresis of the gel and its transfer to the membrane. 
 
Figure 22. a) Quantification (Image J software) of Syntenin-1 in EVs detected by WB showing non significance between 
them; b & c) Gel stained with Coomasie blue and membrane stained with red ponceau confirm correct electrophoresis of 
the gel and its transfer to the membrane; d, e & f) Different membranes with expected Flotilin-1 molecular weight 33 kDa. 
 
In Figure 23, gel stained with Coomasie blue, and membrane stained with red ponceau confirms a 
correct electrophoresis of the gel and its transfer to the membrane. We observed CD81 at the 
described weight in both fraction (Microvesicles and exosomes) in three independent experiments. 
CD81 was 25 kDa and we see that in microvesicles and exosomes are same quantity of this biomarker. 
The relative quantification of the band intensities correspondent to CD81 offered not significant 
differences between CD81 protein expression between microvesicles and exosomes and showed us 




Figure 23. Quantification (Image J software) of CD81 in EVs showing non significance between them; b & c) Gel stained 
with Coomasie blue and membrane stained with red ponceau confirm correct electrophoresis of the gel and its transfer to 
the membrane; d, e & f) Different membranes with expected Flotilin-1 molecular weight 25 kDa. 
 
Analysis of the encapsulation of cTPRAu-390 into EVs  
Percentage of cTPRAu-390 encapsulated under different electroporation conditions is illustrated in 
Table 7. 0.25% and 13,39% of cTPRAu-390 was encapsulated into microvesicles and exosomes 
respectively and used for the experiment of gene expression at 24 h. 1.87% and 4.39% of cTPRAu-
390 was encapsulated into microvesicles and exosomes for the experiment of gene expression at 36 
h. For internalization experiment, was encapsulated 0.98% and 3.57% of cTPRAu-390 into 
microvesicles and exosomes, correspondingly. Finally, 1.87% it was encapsulated into microvesicles 
and 2.77% into exosomes and used for in vivo study. Images of PBS (EVs free) control, cTPRAu-390 
control, non-encapsulated and encapsulated cTPRAu-390 into EVs, non-encapsulated and 
encapsulated cTPRAu-390 stained with BODIPY and DiR are supplemented in Appendix 2 section. 




Genes expression analysis 
Three independent experiments and triplicate for each experiment were performed in this analysis. 
As seen in Figure 24, after 24 hours of incubation of the treated cells there was not variation in Col 
I, Col III or FN gene expression under the following conditions: presence of TGF β, presence of 
TGF β and microvesicles and presence of TGF β and cTPRAu-390 encapsulated into microvesicles.  
 
Figure 24. Lack of variation of Col I, Col III and Fibronectin gene expression after incubation with microvesicles or 
cTPRAu-390 encapsulated into microvesicles for 24 h Student T test. e refers to cTPRAu-390 encapsulated into 
microvesicles, - to Non microvesicles, + to Microvesicles, + to TGF β. 
 
Same conditions used as in the above assays were used for experiment at 36 h for microvesicles and 
exosomes. Three independent experiments and triplicate for each experiment were performed in this 
analysis. 
As is shown in Figure 25, there was not significant difference between treatment with microvesicles 
and control, being significant with the encapsulated therapy. We see that Col I, Col III and 
Fibronectin expression was significantly reduced in presence of cTPRAu-390 encapsulated into 
microvesicles. 
 
Figure 25. Decreased expression of Col I, Col III and Fibronectin gene expression after incubation with cTPRAu-390 
encapsulated into microvesicles for 36 h. Student T test ** P< 0.005; *P <0.05. e cTPRAu-390 encapsulated into 





In Figure 26, we observed a significant difference in Col I expression with unencapsulated exosomes 
treatment, being more significant with cTPRAu-390 encapsulated therapy. For Col III and FN genes, 
there is no significant difference in the column corresponding to the treatment of exosomes without 
encapsulation, being significant with the encapsulated therapy.  
 
Figure 26. Higher decreased expression in Col I, Col III and Fibronectin in the presence of exosomes treatment at 36 h. 
Student T test *** P< 0.0005, ****P<0.0001, * P <0.,05; e cTPRAu-390 encapsulated into exosomes, - Non exosomes, + 
Exosomes, + TGF β. 
 
Detection of EVs internalization 
The following channels were used for the detection and visualization of EVs internalization: the 
merged channel shows the mix of the fluorescence of all channels, mKATE shows the fluorescence 
of the EVs in red, BODIPY fluorescence used to stain the EVs in green, cTPRAu-390 fluorescence 
in blue and the bright field to visualize NIH-3T3 cell shape. All channels are used for non-
encapsulated and encapsulated EVs, except for cTPRAu-390, which is used only for encapsulated 
EVs. 
Figure 27 (Image J Software) illustrates the frames of the timelapse video of the internalization of 
the non-encapsulated microvesicles into the cell visualized in different channels mentioned above.  
The pathway of the microvesicles can be visualized in Figure 27 A & B, then the adherence to the 
cell Figure 27 C and the internalization Figure 27 D. Figures 28 and 29 illustrate the internalization 
of the non-encapsulated microvesicles in the merged and mKATE channel. As mentioned in previous 
sections, since the microvesicles were damaged by electroporation and were not encapsulated, the 




Figure 27. Frames obtained by the timelapse of microvesicles internalization into NIH-3T3 cells. a, b & c) microvesicles 
moving in direction to the plasma membrane, d) internalization into the cell (Image J software). Source: edited by the 
author. 
 
Figure 28. Frames of the internalization of microvesicles visualized by merged channel, microvesicles are represented as 
red-green spots (Image J software). Source: edited by the author. 
 
Figure 29. Frames of the internalization of non-encapsulated microvesicles visualized by mKATE channel, microvesicles 
are represented as red spots (Image J software). Source: edited by the author. 
 
Figure 30 (Image J Software) illustrates the frames of the timelapse video of the internalization of 
the non-encapsulated exosomes into the cell in the different channels. The pathway of the exosomes 
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can be visualized in Figure 30 A, the adherence to the plasmatic membrane (Figure 30 B) and then 
the internalization Figure 30 C. Figures 31 and 32 illustrate closer the internalization of the non-
encapsulated exosomes in the merged channel. 
 
Figure 30. Frames obtained by the timelapse of exosomes internalization. a & b) exosomes moving to the plasmatic 
membrane, c) exosomes internalization into plasma membrane (Image J software). Source: edited by the author. 
 
Figure 31. Frames of the internalization of exosomes visualized by merged channel, exosomes are represented as red-green 




Another event of non- encapsulated exosomes internalization is shown in Figure 32, the movement 
of exosomes into the cell can be visualized in Figure 32 A, B & C and then the internalization in 
Figure 32 D. In Figure 33 is visualized closer the internalization of the non-encapsulated exosomes 
by merged channel and in Figure 34 by mKATE channel. 
 
Figure 32. Frames obtained by the timelapse of exosomes internalization. a, b & c) exosomes moving to the plasmatic 
membrane, c) exosomes internalization into NIH-3T3 cell (Image J software). Source: edited by the author. 
 
Figure 33. Frames of the internalization of exosomes visualized by merged channel, exosomes are represented as red-green 




Figure 34. Closer visualization of the internalization of exosomes into NIH-3T3 cell shown in mKATE channel, exosomes 
are represented as red spots (Image J software). Source: edited by the author. 
 
Figure 35 (Image J Software) illustrates the frames of the timelapse video of the internalization of 
cTPRAu-390 encapsulated into exosomes in the different channels. Exosomes are seen moving 
toward the plasma membrane as visualized in Figure 35 A & B, get attached to the cell Figure 35 C 
and then the internalization Figure 35 D. Figure 36 demonstrates the internalization of the 
cTPRAu-390 encapsulated into exosomes visualized by the merged channel.  
  
Figure 35. Frames obtained by the timelapse of cTPRAu-390 encapsulated into exosomes internalization. a, b & c) 
exosomes moving to the plasmatic membrane, d) exosomes internalization into NIH-3T3 cell (Image J software). Source: 




Figure 36. Closer illustration of cTPRAu-390 encapsulated into exosomes internalizing in the cell (Image J software) 
visualized in merged channel. Source: edited by the author. 
 
The internalization of EVs in the cell was confirmed by confocal imaging in which the same channels 
were used. It is shown in Figures 37 and 38 the merged of different channels and it is demonstrated 
the internalization into the cell of the encapsulated nanocluster. Figure 37 corresponds to non-
encapsulated microvesicles and Figure 38 to cTPRAu-390 encapsulated into exosomes. 
 
Figure 37. Non encapsulated cTPRAu-390 into microvesicles: a) Merge of different channels in which yellow color is the 
result of the mix of mKATE and Bodipy fluorescence, b) red fluorescence corresponds to microvesicles, c) green 
fluorescence by stained microvesicles, d) cTPRAu-390 blue fluorescence, as the microvesicles were not encapsulated, there 




Figure 38. Confocal images showing exosomes and cTPRAu-390 detection: a) all channels combine b) red fluorescence of 
exosomes, c) green fluorescence by stained exosomes, d) cTPRAu-390 blue fluorescence, e) bright field to visualize NIH-
3T3 cell shape (Image J software). Source: edited by the author. 
 
EVs distribution in fibrotic mice through in vivo imaging and after EVs 
administration 
The Spectral Unmixing in vivo at time 0 is illustrated in Figure 39. It is observed autofluorescence as 
green in control mouse, nor fluorescence in mouse with exosomes, whereas in mice with 





Figure 39. In vivo imaging to detect EVs at time points 0 after their IP administration.  The Spectral Unmixing at time 0: a) 
tissue autofluorescence in mice, b) EVs fluorescence present in mice with exosomes and microvesicles, c) composite of 
both fluorescences in which green autofluorescence is noticed in control mouse and microvesicles-mouse with blue 
fluorescence.  
 
Figure 40 shows the Spectral Unmixing in vivo at time 24 h, control mouse did not present any 
fluorescence, in the mouse with exosomes blue fluorescence starts to be noticed and in the one with 
microvesicles it is seen that the fluorescence has started to be distributed from the area of 




Figure 40. In vivo imaging to detect EVs at time points 24 h after their IP administration.  The Spectral Unmixing at time 
24 h: a) tissue autofluorescence in both treated mice, b) EVs fluorescence detected in both mice, c) in composite blue 
fluorescence more distributed in the mouse with microvesicles than the one with exosomes. 
 
And for time 6 days in Figure 41, in vivo Spectral Unmixing shows that the fluorescence is more 
defined in the middle part of the mouse with exosomes while the one with microvesicles shows a 
greater distribution of fluorescence from the site of administration up to the heart area and mouth; 
the presence of fluorescence on the left side of the experimental animal was most noticeable than the 




Figure 41. In vivo imaging to detect EVs at time points 6 days after their IP administration.  The Spectral Unmixing at time 
6 days:  a & b) shows higher distribution in mouse with microvesicles than one with exosomes, c) the presence of 
microvesicles on the left side from the site of administration in the cranial direction is mainly highlighted. 
 
Figure 42 shows ex vivo Spectral Unmixing, fluorescence is seen in the gut, stomach, and liver in both 
treated mice. In composite it is also observed lungs autofluorescence in green that corresponds to 




Figure 42. In vivo imaging to detect EVs ex vivo at time points 6 days after their IP administration.  Ex vivo Spectral 
Unmixing:  a) organs autofluorescence, b) EVs fluorescence, c) composite of both fluorescence in which green its tissue 
autofluorescence and in blue EVs fluorescence. 
 
5. Discussion 
CDV is one of the most impactful diseases around the world in which cardiac fibrosis appears as a 
common hallmark in almost all CDV (Hinderer & Schenke-Layland, 2019). Cardiac fibrosis is the 
pathological result of a tissue repair response to different types of tissue injury, characterize by the 
excessive accumulation of ECM compounds and the excessive proliferation of fibroblasts, indeed 
about 800,000 people die annually due to fibrotic pathologies accounting for 45% of all deaths 
worldwide, being cardiac and pulmonary fibrosis main accounts(Ding et al., 2020; Henderson et al., 
2020; Hinderer & Schenke-Layland, 2019).   
Nowadays, it is known that there is no treatment to cure cardiac fibrosis, but different diagnostic and 
treatment tools are currently being studied (Gyöngyösi et al., 2017; Villar et al., 2013).  
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In this study, we analyze a new experimental approach to reduce myocardial fibrosis, including a bio-
transporter encapsulating an antifibrotic therapeutic strategy.  
We have isolated, characterized and analyzed extracellular vesicles as transport vehicles for the 
cTPRAu-390 therapy created to decrease the expression of profibrotic genes by blocking the TFG β 
signaling cascade through its binding to the C-terminal Hsp90 domain (Cáceres et al., 2018; García 
et al., 2016).We measured protein concentration (absorbance at 280 nm) to infer the yield of each 
isolation.  Whereas we have performed all isolations under the same conditions, we obtained a range 
of concentration for the EVs isolation we performed, probably depending on the final number of 
cells we started with. The confluence of cells varied between 75-95%. 
Considering that ISEV defines large vesicles (microvesicles) as those measuring > 200 nm while small 
vesicles (exosomes) are those vesicles <100 nm or <200 nm, we can say that our population of both 
microvesicles and exosomes are within the ranges (Lamichhane et al., 2015; Théry et al., 2018) by 
electron microscopy detections. 
Another important characteristic to be taken into account about EVs, is their charge. With Zsizer we 
could detect a neutral charge for microvesicles and a negative charge for exosomes population. It is 
known that a negative charge is normal in EVs population, also that the closer to neutral in charge 
the more stable they will be in circulation, charge is highly dependent on the concentration of sugar 
present in the membrane (de Abreu et al., 2020; Théry et al., 2018). Together with the measurements 
of flow cytometry, DLS was used to characterize the size of the vesicles, but reliable data could not 
be obtained since the size of the exosomes compared to the microvesicles was similar, considering 
that previously it was seen by electron microscopy that they differ in size. One reason could be that 
samples analyzed were placed in PBS EVs free and that samples need to be placed in a different type 
of buffer; other reason could be that samples used for light scattering were analyzed after 4-5 days 
from being isolated which could mean that EVs formed aggregates. Changes in morphology, size and 
composition when storing at 4°C have been already described (Théry et al., 2018). 
As seen in Figures 19 and 20 in results section, both microvesicle and exosome populations as 
mentioned in the protocol by which the characterization of the EVs population was carried out, we 
obtained the expected population shape in EVs by flow cytometry as shown in red mark in figures 
already mentioned (Rotator et al., 2015). 
Considering that the isolation process of EVs is long and that the storage time influences their 
characterization, studies on the type of storage should be carried through. Also, it should be studied 
how to obtain pellets that are not so dense, given the difficulty of resuspending them completely, 
thus leaving part of the EVs in the non-resuspended ones.  
WB analysis revealed two cytosolic-proteins and one transmembrane protein presented in EVs. As 
shown in Figure 21, Flotillin-1 expression was detected in both populations microvesicles and 
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exosomes with non-significant difference between them. Flotillin-1 is a cytosolic protein with lipid-
protein or membrane-protein binding ability, these expected marker confirms that microvesicles and 
exosomes have lipid bilayers capable of enclosing intracellular material. Another cytosolic protein we 
detected was Syntnein-1 as shown in Figure 22. The protein was present in both populations and 
with no representative difference in the amount between them. Syntenin-1 is involved in 
transmembrane trafficking and exosome biogenesis. Finally, CD81 protein was detected as shown in 
Figure 23, in both EVs population, with no relevant difference in the amount of protein between 
them. CD81 is a transmembrane protein, the presence of this marker demonstrates the specific lipid 
structure of the microvesicles upon bud to the plasma membrane and of the exosomes after transit 
of the endosomal pathway (Doyle & Wang, 2019; Ha et al., 2016; Kalra et al., 2012; Pathan et al., 
2019; Théry et al., 2018; Tiwari et al., 2021). According to data obtained from vesiclepedia, Flotillin-
1 has been identified 259 times and CD81 262 times in EVs (Kalra et al., 2012; Pathan et al., 2019).  
After characterizing and confirming that the vesicles obtained belong to microvesicles and exosomes, 
the cTPRAu-390 nanocluster was encapsulated into EVs by electroporation. To confirm nanocluster 
encapsulation, flow cytometry technique was used to measure the percentage of cTPRau-390 
encapsulated into EVs, obtaining different percentages of encapsulation.  
To be used for in vitro experiment at 24 h and 36 h, as shown in Table 7, 2 electroporation pulses 
were applied obtaining a low percentage of encapsulation in microvesicles compared to exosomes. 
In the encapsulation to be used for the internalization assay, we changed the number of pulses of 
electroporation for microvesicles to 5 pulses given its low percentage of encapsulation and for 
exosomes to 3 pulses to see if there was more % of encapsulation; having that microvesicles were 
damaged and there was no increase in its percentage, as can be seen in the attached figures in 
Appendix 2 section, the shape of the population in flow cytometry was altered in comparison with 
exosomes. Finally, in the encapsulation to be used for in vivo experiment 2 pulses were applied, but 
there was not a higher encapsulation for microvesicles nor a higher change for exosomes. These 
results show that the number of pulses directly influences the encapsulation percentage, 2 pulses 
should be given to microvesicles because as it was observed in the results an increasing number of 
pulses to 5 led to damage to the vesicles and increasing to 3 there was no apparent difference. While 
for exosomes it can be said that the optimum number of pulses is 2 since increasing it to 3 showed 
no change (Lamichhane et al., 2015). More studies should be done on the type of encapsulation for 
microvesicles because although electroporation did not have a high encapsulation rate, it did have an 
effect on the decrease of profibrotic genes expression, so studying other methods of encapsulation 
for example a passive loading method as co-incubation in which the morphology of EVs is preserved 
so it could increase the effectiveness of this vesicle as a transport vehicle (Villata et al., 2020). In the 
same way, different conditions of electroporation for exosomes should be studied to see if a higher 
percentage of encapsulation is obtained than the one used in this work. Encapsulation methods such 
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as saponin treatment or hypotonic dialysis can be studied since it is known that they do not alter the 
constitution and functionality of the EVs (Fuhrmann et al., 2015).  
As described in results section, once we encapsulated the nanocluster into EVs we proceeded to 
apply different treatments to NIH-3T3 cells to analyze gene expression. In the 24-hour treatment, no 
variation was seen in the expression of Col I, Col III or FN genes under the established conditions. 
While in the 36-hour treatment there was no significant difference with the non-encapsulated 
microvesicles treatment but there was a significant decrease in Col I, Col III and FN genes in the 
presence of the encapsulated therapy, whereas in the exosome treatment a greater effect in the 
decrease of the expression of the genes of interest was observed. What drew our attention to the 
exosome treatment is that in Col I, in addition to the effect of the encapsulated treatment, the non-
encapsulated exosomes also had a positive effect on the decrease of expression. There was a greater 
decrease in the expression of Col III (** P<0.005) than Col I (*P<0.05) and FN (*P<0.05) compared 
to the controls. These results could indicate that the vehicle (EVs) could also be a therapeutic solution 
because is capable of reducing the expression of collagens, thus reducing fibrosis. This result is highly 
interesting because was additive with the presence of the antifibrotic nanocluster, providing an 
increase in the reduction of profibrotic genes expression. 
Despite the lower amount of exosomes compared to microvesicles, there was a greater decrease in 
expression of the profibrotic genes but with a higher percentage of encapsulation so it may have 
more cTPRAu-390 than microvesicles. As we saw exosomes without therapy also decrease 
expression, what leads us to think that since exosomes are extracted from non-activated fibroblasts, 
there may be a synergistic effect in their ability to reduce gene expression, which in itself may be a 
better vehicle than microvesicles, because they are better encapsulated and they already have 
properties in their composition that help to decrease these expressions. So, it would be interesting 
and important to further study their composition and which components makes this expression 
decrease.  
We can confirm that the results obtained in terms of fibrosis reduction are due to the presence of the 
fluorescent exogenous EVs incorporated to cells. This can be affirmed with the internalization of 
EVs into NIH-3T3 cells by live cell microscopy, as shown in Figures 28-36 in results section. 
In vivo images shown that at 0 hours in exosomes mouse was non visualized distribution instead in 
microvesicles-mouse appeared fluorescence at the site of administration. At 24 hours the distribution 
of fluorescence was seen upwards towards the heart in microvesicles-mouse and exosomes- mouse 
started to present fluorescence; and after 6 days the distribution of the therapy from the area of 
administration to the mouth. It captures our attention the fact that it is mostly visualized on almost 
the entire left side compared to the right side in which only the injection zone is appreciated.  In the 
ex vivo images, fluorescence was seen in the stomach, gut, and liver. It could mean that in the gut and 
stomach it is found due to the method of administration and in the liver, because it was already 
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degrading. What remains to be done is to extract RNA and DNA from the heart to know if the 
therapy reached the heart and if there was a decrease in the expression of the profibrotic genes. We 
should also extract RNA and DNA from the skin to know if the fluorescence observed is also due 
to the binding to the skin or because of our nanocluster. More in vivo experiments should be 
performed to obtain the exact time point in which EVs locate in the heart.  
 
6. Conclusions 
The protocol used for isolation has been demonstrated by EVs characterization. 
The time of storage of EVs can influence in its morphology, size, and composition. 
Electroporation is better encapsulation method to be used in exosomes than for microvesicles. 
It is also concluded that the number of pulses in electroporation process influences in the percentage 
of encapsulation. 
It must be said that exosomes are better vehicle transporting our therapy to treat fibrosis given the 
higher degree of reduction in the expression of profibrotic genes than microvesicles. 
Exosomes isolated from inactivated fibroblasts are vesicles that could carry in their composition a 
component capable of reducing cardiac fibrosis so in addition to being used as a vehicle it could be 
used also as a therapy. 
We have demonstrated that extracellular vesicles can be used as biological vehicles to transport 
potential nano-therapeutic strategies for the treatment of cardiac fibrosis given multiple advantages. 
Therapies encapsulated in extracellular vesicles can be internalized into cells. 
Bodipy and DiR are good dyes to stained EVs due to the fact they do not alter EVs morphology and 
have a good signal intensity when visualized. 
EVs engineered to fluoresce can be administered in vivo without losing their morphology and capable 
of revealing their distribution.  
The cTPRAu-390 nanocluster can be used as a theragnostic tool to treat cardiac fibrosis observed in 
NIH-3T3 cell model. 
It is concluded that the sacrifice of the experimental animals after 6 days of administering this therapy 
turns to be a long period of time to perform the ex vivo study, since it was only possible to observe 
the degradation in the liver. Therefore, studies should be carried out at shorter periods to appreciate 
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Appendix 1. TEM 
 
 
Appendix 1.1. Microvesicles visualized by electron microscopy. a) different diameter sizes, b) microvesicles without their 







Appendix 1.2. Exosomes visualized by electron microscopy. a) different diameter sizes, b) exosomes without their diameter 










Appendix 2. Flow cytometry  
 
Appendix 2.1. PBS EVs free used as control to characterize EVs population, red mark region aside from EVs region. 
 
Appendix 2.2. cTPRAu-390 control analyzed to confirm that it is free of EVs used in 24 and 36 h experiment. 
 
Appendix 3. ctPRAu-390 encapsulation into microvesicles for 24h treatment. On the left side red region refers to% of 
non-encapsulated microvesicles used as control to be compared to right side red mark which represents 0.25 % of 
nanocluster encapsulated into microvesicles. 
 
 
Appendix 2.3. ctPRAu-390 encapsulation into microvesicles for 24h treatment. On the left side red region refers to % of 
non-encapsulated exosomes used as control to be compared to right side red mark which represents 13.39 % of nanocluster 
encapsulated into exosomes. 
 
Appendix 2.4. ctPRAu-390 encapsulation into microvesicles to be used in 36h treatment. Red region refers to 1.87 % of 
nanocluster encapsulated into microvesicles. 
 
Appendix 2.5. ctPRAu-390 encapsulation into exosomes for 36h treatment. On the left side red region refers to % of non-
encapsulated exosomes used as control to be compared to right side red mark which represents 4.39 % of nanocluster 
encapsulated into exosomes. 
 
 
Appendix 2.6. cTPRAu-390 encapsulation into microvesicles to be use in internalization experiment. On the left side, the 
area marked in red represents the normal region shape of microvesicles while on the right side is an altered form due to 5 
pulses given in the electroporation given a 0.98% of encapsulation. 
 
 
Appendix 2.7. cTPRAu-390 encapsulation into exosomes to be used in internalization experiment. On the left side, the 
area marked in red represents 3.57 % of nanocluster encapsulated into exosomes stained with bodipy. 
 
Appendix 2.8. ctPRAu-390 encapsulation into microvesicles stained with DiR to be used in vivo experiment. On the left 
side red region refers to % of non-encapsulated microvesicles used as control to be compared to right side red mark which 







Appendix2.9. cTPRAu-390 encapsulation into exosomes stained with DiR to be used at in vivo experiment. a) red mark 
region refers to % of non-encapsulated exosomes used as control to be compared to b) red mark which represents 2.77 % 













Appendix 3. In vivo spectral unmixing 
 
        
 
 
Appendix3.1. Spectral unmixing: control mice at the left doesn’t present fluorescence at any time, a) t=0 h exosome-
mouse with fluorescence at site of administration and microvesicle-mouse fluorescence in the lower part; b) t=24 h 
presence of fluorescence at lower part of exosome-mouse and a distribution of fluorescence up towards in microvesicle-
mouse; c) t= 6 days fluorescence is more defined in the lower part of exosome-mouse and more defined fluorescence 
distributed in the upper part up to its mouth in microvesicle mouse. 
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